JP7581219B2 - ニューモシスチス属種（Ｐｎｅｕｍｏｃｙｓｔｉｓ ｓｐｐ．）肺炎を治療又は予防するためのトリテルペノイド系抗真菌薬 - Google Patents

ニューモシスチス属種（Ｐｎｅｕｍｏｃｙｓｔｉｓ ｓｐｐ．）肺炎を治療又は予防するためのトリテルペノイド系抗真菌薬 Download PDF

Info

Publication number
JP7581219B2
JP7581219B2 JP2021549801A JP2021549801A JP7581219B2 JP 7581219 B2 JP7581219 B2 JP 7581219B2 JP 2021549801 A JP2021549801 A JP 2021549801A JP 2021549801 A JP2021549801 A JP 2021549801A JP 7581219 B2 JP7581219 B2 JP 7581219B2
Authority
JP
Japan
Prior art keywords
formula
compound
pharma
pharmaceutical composition
pneumocystis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021549801A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523212A5 (https=
JP2022523212A (ja
JPWO2020176527A5 (https=
Inventor
アングロ・ゴンザレス，デイビット・エー
バラ，ステファン・アンドリュ
Original Assignee
サイネクシス，インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サイネクシス，インコーポレーテッド filed Critical サイネクシス，インコーポレーテッド
Publication of JP2022523212A publication Critical patent/JP2022523212A/ja
Publication of JP2022523212A5 publication Critical patent/JP2022523212A5/ja
Publication of JPWO2020176527A5 publication Critical patent/JPWO2020176527A5/ja
Application granted granted Critical
Publication of JP7581219B2 publication Critical patent/JP7581219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
JP2021549801A 2019-02-27 2020-02-25 ニューモシスチス属種（Ｐｎｅｕｍｏｃｙｓｔｉｓ ｓｐｐ．）肺炎を治療又は予防するためのトリテルペノイド系抗真菌薬 Active JP7581219B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811456P 2019-02-27 2019-02-27
US62/811,456 2019-02-27
PCT/US2020/019724 WO2020176527A1 (en) 2019-02-27 2020-02-25 Triterpenoid antifungals for the treatment or prevention of pneumocystis spp. pneumonia

Publications (4)

Publication Number Publication Date
JP2022523212A JP2022523212A (ja) 2022-04-21
JP2022523212A5 JP2022523212A5 (https=) 2023-02-24
JPWO2020176527A5 JPWO2020176527A5 (https=) 2023-02-24
JP7581219B2 true JP7581219B2 (ja) 2024-11-12

Family

ID=70005768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021549801A Active JP7581219B2 (ja) 2019-02-27 2020-02-25 ニューモシスチス属種（Ｐｎｅｕｍｏｃｙｓｔｉｓ ｓｐｐ．）肺炎を治療又は予防するためのトリテルペノイド系抗真菌薬

Country Status (15)

Country Link
US (1) US12594266B2 (https=)
EP (1) EP3930716B1 (https=)
JP (1) JP7581219B2 (https=)
KR (1) KR20210133241A (https=)
CN (1) CN113631165A (https=)
AU (1) AU2020228036B2 (https=)
BR (1) BR112021016876A2 (https=)
CA (1) CA3131298A1 (https=)
EA (1) EA202192344A1 (https=)
ES (1) ES3055272T3 (https=)
IL (1) IL285839A (https=)
MA (1) MA55081A (https=)
MX (2) MX2021010311A (https=)
TW (1) TWI910099B (https=)
WO (1) WO2020176527A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028034A1 (en) 2017-08-04 2019-02-07 Scynexis, Inc. Antifungal agents with enhanced activity in acidic ph

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166135A (en) * 1988-09-12 1992-11-24 Merck & Company, Inc. Method for the control of pneumocystis carinii
DK173802B1 (da) * 1988-09-12 2001-11-05 Merck & Co Inc Præparat til behandling af Pneumocystis carinii infeksioner og anvendelse af et cyclohexapeptid til fremstilling af et lægemiddel mod Pneumocystis carinii infektioner
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
JP5245057B2 (ja) 2006-04-03 2013-07-24 メルク・シャープ・アンド・ドーム・コーポレーション 抗真菌剤
WO2010019204A1 (en) 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
CN108883152A (zh) * 2016-01-08 2018-11-23 奇达拉治疗公司 防止和治疗肺孢子虫感染的方法
MA49889A (fr) * 2017-04-10 2020-06-24 Scynexis Inc Agents antifongiques utilisés en association

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019028034A1 (en) 2017-08-04 2019-02-07 Scynexis, Inc. Antifungal agents with enhanced activity in acidic ph

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Melanie Cushion et al.，"P1226 SCY-078 demonstrates antifungal activity against pneumocystis in a prophylactic murine model of pneumocystis pneumonia"，28th European Congress of Clinical Microbiology and Infectious Diseases，2018年，P1226

Also Published As

Publication number Publication date
MX2021010311A (es) 2022-01-04
JP2022523212A (ja) 2022-04-21
KR20210133241A (ko) 2021-11-05
WO2020176527A1 (en) 2020-09-03
US12594266B2 (en) 2026-04-07
AU2020228036A1 (en) 2021-09-23
TWI910099B (zh) 2026-01-01
MA55081A (fr) 2022-01-05
AU2020228036B2 (en) 2025-08-07
EP3930716B1 (en) 2025-09-10
IL285839A (en) 2021-10-31
EP3930716A1 (en) 2022-01-05
CN113631165A (zh) 2021-11-09
BR112021016876A2 (pt) 2021-11-03
MX2025004197A (es) 2025-09-02
ES3055272T3 (en) 2026-02-10
CA3131298A1 (en) 2020-09-03
TW202045169A (zh) 2020-12-16
US20230149376A1 (en) 2023-05-18
EA202192344A1 (ru) 2021-11-15

Similar Documents

Publication Publication Date Title
US20260000656A1 (en) Antifungal agents with enhanced activity in acidic ph
JP7581219B2 (ja) ニューモシスチス属種（Ｐｎｅｕｍｏｃｙｓｔｉｓ ｓｐｐ．）肺炎を治療又は予防するためのトリテルペノイド系抗真菌薬
US20250248983A1 (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40066679A (en) Triterpenoid antifungals for the treatment of pneumocystis spp. pneumonia
HK40066679B (en) Triterpenoid antifungals for the treatment of pneumocystis spp. pneumonia
HK40062347A (en) Triterpenoid antifungals for the treatment or prevention of pneumocystis spp. pneumonia
HK40091926A (en) Antifungal agents with enhanced activity in acidic ph
HK40062374B (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40062374A (en) Triterpenoid antifungals for the treatment of fungal osteo-articular infections
HK40030410A (en) Antifungal agents with enhanced activity in acidic ph
HK40030410B (en) Antifungal agents with enhanced activity in acidic ph
EA047126B1 (ru) Противогрибковое средство для лечения или профилактики инфекции вульвовагинального кандидоза

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230215

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240123

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240719

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241030

R150 Certificate of patent or registration of utility model

Ref document number: 7581219

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150